IL6R and interstitial lung disease: In addition, tocilizumab as monotherapy can stabilize or even improve ILD (96), and as an IL-6 receptor antagonist, tocilizumab can achieve anti-fibrotic effects by blocking IL-6R, which means this treatment delivers potential benefits in RA-ILD-associated pulmonary fibrosis (97).